Abstract 286P
Background
Recurrent tumors on MRI described as intermediate T2 signal intensity and ADC quantitative values derived from diffusion sequences are prone to discrepancy. In post surgical setting of oral cavity ADC values are prone to artifacts limiting its utility. This investigation aims to build a decision model using quantitative robust parameters derived from MR imaging.
Methods
Four lesion quantitative parameters ( quantitative T2 lesion signal, T2 lesion/muscle signal ratio, T2 lesion /Tongue signal ratio and ADC values) were assessed in 68 lesions (54 malignant,14 benign). Classification analysis was performed using L1 regularization of features in a Logistic regression, Statistical feature selection methods like ANOVA f-value and chi square and lastly a Entropy based feature selection using decision tree. Results include the probability for malignancy for every descriptor combination in the classification tree. Area under the curve (AUC) used as the statistical parameters to find model efficiency was calculated using software "R".
Results
Logistic regression based classifier could predict the probability of cancer based on T2 based features alone. ADC was not found helpful in predicting the disease. Both scores obtained from ANOVA and Chi-square have a different assumptions about distributions of input feature values and output probabilities, but yielded different scores. Both methods point to T2 as most significant in predicting output probabilities of cancer. Lastly, the decision tree showed T2 based features in addition to ADC provide maximum diagnostic value in determining cancer in patients. The area under the curve of the ROC was .940 for additive T2 and ADC and only 0.74 for ADC values alone. The signal ratios (T2 lesion/muscle signal ratio and T2 lesion /Tongue signal ratio) have an AUC 0.96.
Conclusions
Though each method of feature selection has certain shortfalls due to the assumptions but results demonstrate T2 feature outranking all others, indicating its high predictive power in determining the probability of disease. It is therefore possible to train predictive robust models based on T2 quantitative features with high level of accuracy and precision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session